Exchange: OTC·Updated 07:30 PM EST

ELOX News

News
all
press releases
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdatePR NewswireARLINGTON, Mass., Nov. 16, 2026 Dosed first two patients in global Phase 2b EXACT study of...
PR Newswire
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business UpdatePR NewswireARLINGTON, Mass., Nov. 16, 2026 Dosed first two patients in global Phase 2b EXACT study of...
PR Newswire
More News
Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation ConferencePR NewswireARLINGTON, Mass., Nov. 2, 2026 ARLINGTON, Mass., Nov. 2, 2026 /PRNewswire/ -- Eloxx...
PR Newswire
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKDPR NewswireARLINGTON, Mass., Oct. 29, 2026 FDA...
PR Newswire
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical...
PR Newswire
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of DirectorsPR NewswireARLINGTON, Mass., Oct. 19, 2026 Mr. Germano brings more than 35 years of...
PR Newswire
Analysts initiated coverage: Neutral on RDW, Overweight on ELOX, Buys on SGHT and AU, and Market Perform on FFIN.read more...
Benzinga
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport SyndromePR NewswireARLINGTON, Mass., Sept. 11, 2026...
PR Newswire
(RTTNews) - Eloxx Pharmaceuticals, Inc. (ELOX) reported Loss for second quarter of -$4.50 million...
Nasdaq News: Markets
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire ARLINGTON, Mass., Aug. 12, 2026 Completed underwritten public offering with gross proceeds of...
PR Newswire
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq PR Newswire ARLINGTON, Mass., June 8, 2026 ARLINGTON, Mass., June 8, 2026 /PRNewswire...
PR Newswire

Advertisement|Remove ads.